More than 20 pharma companies are taking part in the COVID Research and Development Alliance that will hunt for new coronavirus treatments among existing therapies.
This week, the group announced that it is launching trials for a number of treatments including Amgen’s psoriasis drug, Otezla, an anti-inflammatory by Takeda called lanadelumab and UCB’s zilucpolan, which helps moderate the body’s immune system response.
The goal for the trials is to find treatments that help patients severely ill with COVID-19.
The COVID R&D group plans to trial other drugs, including antivirals, in the coming months. All of the treatments will be tested against a placebo.
Read the full Reuters report.
